In Changing RNAi Rx Guidance, Pfizer Becomes Latest Big Pharma to Shift Expectations | GenomeWeb

By Doug Macron

When Pfizer pulled back from a commitment to file an investigational new drug application on an RNAi candidate next year, it joined a small but growing list of big pharmas that have ostensibly run into difficulties developing the gene-silencing technology for therapeutic applications.

At the same time, a handful of RNAi drug shops have found forging alliances with pharmaceutical firms to be challenging, in some cases and on several occasions missing previous partnership guidance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.